Capstan Therapeutics to Participate in Upcoming Investor Conferences

News > Business News

Audio By Carbonatix

7:30 AM on Thursday, November 14, 2024

The Associated Press

SAN DIEGO--(BUSINESS WIRE)--Nov 14, 2024--

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that the Company will participate in the following industry conferences:

Stifel Healthcare Conference
Date: Tuesday, November 19, 2024
Time: 2:25-2:55 p.m.
Location: Lotte New York Palace Hotel, 4 th Floor – Kennedy

President and Chief Executive Officer Laura Shawver, Ph.D., will give a company presentation and members of Capstan management will participate in 1x1 investor meetings.

36th Annual Piper Sandler Healthcare Conference
Date: Tuesday, December 3, 2024
Time: 2:10-2:30 p.m.
Location: Lotte New York Palace Hotel, 4 th Floor – Kennedy 1

Chief Medical Officer Ramin Farzaneh-Far, M.D., will give a company presentation and members of Capstan management will participate in 1x1 investor meetings.

About Capstan Therapeutics, Inc. (www.capstantx.com)
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of novel LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter ).

View source version on businesswire.com:https://www.businesswire.com/news/home/20241114357775/en/

CONTACT: Investors:

Miguel Arcinas

Senior Vice President of Corporate Development

Capstan Therapeutics

[email protected]

Media:

Rhiannon Jeselonis

Ten Bridge Communications

[email protected]

KEYWORD: CALIFORNIA NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: ONCOLOGY HEALTH STEM CELLS GENETICS PHARMACEUTICAL BIOTECHNOLOGY